A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).
Inclusion Criteria:
Exclusion Criteria:
Participate-In-This-Study1@its.jnj.com844-434-4210
Irvine, California 92618, United States
Orange, California 92868, United States
San Francisco, California 94115, United States
San Francisco, California 94143, United States
Walnut Creek, California 94596, United States
Newark, Delaware 19713, United States
Washington D.C., District of Columbia 20007, United States
Fort Lauderdale, Florida 33316, United States
St. Petersburg, Florida 33701, United States
West Palm Beach, Florida 33401, United States
Chicago, Illinois 60607, United States
Mineola, New York 11501, United States
New York, New York 10016, United States
New York, New York 10032, United States
Winston-Salem, North Carolina 27157, United States
Eugene, Oregon 97401, United States
Bryn Mawr, Pennsylvania 19010, United States
Paoli, Pennsylvania 19301, United States
Thessaloniki, 54639, Greece
Warsaw, 02-781, Poland
Greater London, SE1 9RT, United Kingdom